



**CORPORATE ACTION NOTICE
TERMINATION NOTICE**

March 12, 2026

Revised

**NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES ("ADSs") EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS ("ADRs")
REPRESENTING DEPOSITED ORDINARY SHARES OF:
INVICTUS THERAPEUTICS LTD.
ONE ADS REPRESENTS FORTY ORDINARY SHARES
CUSIP: 608458204 AND UNDERLYING ISIN: AU0000152597**

You were previously notified, as owners and beneficial owners of the above American Depositary Receipts ("ADRs"), that we were to terminate the Deposit Agreement, dated June 26, 2014, among Invictus Therapeutics Ltd. (f/k/a VGI Health Technology Limited ; f/k/a Azure Health Technology Ltd ; f/k/a Moko Social Media limited) ("Invictus Therapeutics"), The Bank of New York Mellon ("BNYM"), as Depositary, and Owners and Holders of American Depositary Shares (the "Deposit Agreement"). As a result, the existing ADR facility was terminated effective at 5:00 PM (Eastern Time) on June 18, 2018.

Currently there is no public trading market for Invictus Therapeutics Ltd ordinary shares as they were suspended from official quotation on the Australian Stock Exchange on January 25, 2017. BNYM's custodian in Australia has sent notification that transfer, movement, conversion and settlement of the shares is not possible. Accordingly, delivery of those shares upon surrender and cancellation of the ADRs and/or sale of those shares is not practicable or possible.

Holders were previously advised that there is currently no public trading market for the company's ordinary share. The Depositary will not be able to sell the shares or receive any value for the shares.

Subsequent to the termination, the Company has undergone a name change. As a result, effective December 16, 2025, the Company's name changed to Invictus Therapeutics Ltd (f/k/a VGI Health Technology Limited; f/k/a Azure Health Technology Ltd.; f/k/a Moko Social Media Limited).

BNYM has closed its books for issuance and cancellation.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

For Settlement specific inquiries, please contact DRsettlements@bnymellon.com

Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY. In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary. In such cases, BNY has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed at https://www.adrbny.com/content/dam/adr/documents/fees-and-disclosures-pdf/drs_foreign_exchange_pricing_disclosure.pdf.

In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or to ensure that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency. In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is the most favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY.

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED

CORPORATE ACTION NOTICE

TERMINATION NOTICE



Aug 3, 2021

Revised

**NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS (“ADRs”)
REPRESENTING DEPOSITED ORDINARY SHARES
VGI Health Technology Limited
(f/k/a Azure Health Technology Ltd; f/k/a Moko Social Media Limited)
ONE ADS REPRESENTS FORTY ORDINARY SHARES
CUSIP: 608458204 AND UNDERLYING ISIN: AU0000152597**

You were previously notified, as owners and beneficial owners of the above American Depositary Receipts (“ADRs”), that we were to terminate the Deposit Agreement, dated June 26, 2014, among VGI Health Technology Limited (f/k/a Azure Health Technology Ltd ; f/k/a Moko Social Media limited) (“VGI Health Technology”), The Bank of New York Mellon (“BNYM”), as Depositary, and Owners and Holders of American Depositary Shares (the "Deposit Agreement"). As a result, the existing ADR facility was terminated effective at 5:00 PM (Eastern Time) on June 18, 2018.

Currently there is no public trading market for VGI Health Technology ordinary shares as they were suspended from official quotation on the Australian Stock Exchange on January 25, 2017. BNYM’s custodian in Australia has sent notification that transfer, movement, conversion and settlement of the shares is not possible. Accordingly, delivery of those shares upon surrender and cancellation of the ADRs and/or sale of those shares is not practicable or possible.

Holders were previously advised that there is currently no public trading market for the company’s ordinary share. The Depositary will not be able to sell the shares or receive any value for the shares.

Subsequent to the termination, the Company has undergone a name change. As a result effective July 14, 2021, the Company’s name changed to VGI Health Technology Limited (f/k/a Azure Health Technology Ltd.; f/k/a Moko Social Media Limited).

BNYM has closed its books for issuance and cancellation.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbnymellon.com.



Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

BNY Mellon may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY Mellon. In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY Mellon acts as principal counterparty and not as agent, advisor, broker or fiduciary. In such cases, BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or can be accessed at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/drs_foreign_exchange_pricing_disclosure.pdf.

In those instances where BNY Mellon's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or to ensure that the method by which the rate will be determined will be the most favorable rate, and BNY Mellon makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, BNY Mellon may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency. In such cases, BNY Mellon will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is the most favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

CORPORATE ACTION NOTICE

TERMINATION NOTICE



June 3, 2019

Revised

**NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS (“ADRs”)
REPRESENTING DEPOSITED ORDINARY SHARES**

Azure Health Technology Ltd (f/k/a Moko Social Media Limited)

ONE ADS REPRESENTS FORTY ORDINARY SHARES

CUSIP: 608458204 AND UNDERLYING ISIN: AU0000038879

You were previously notified, as owners and beneficial owners of the above American Depositary Receipts (“ADRs”), that we were to terminate the Deposit Agreement, dated June 26, 2014, among Azure Health Technology Ltd(f/k/a Moko Social Media limited) (“Azure Health Technology”), The Bank of New York Mellon (“BNYM”), as Depositary, and Owners and Holders of American Depositary Shares (the "Deposit Agreement"). As a result, the existing ADR facility was terminated effective at 5:00 PM (Eastern Time) on June 18, 2018.

Currently there is no public trading market for Azure Health Technology ordinary shares as they were suspended from official quotation on the Australian Stock Exchange on January 25, 2017. BNYM’s custodian in Australia has sent notification that transfer, movement, conversion and settlement of the shares is not possible. Accordingly, delivery of those shares upon surrender and cancellation of the ADRs and/or sale of those shares is not practicable or possible.

Holders were previously advised that there is currently no public trading market for the company’s ordinary share. The Depositary will not be able to sell the shares or receive any value for the shares.

Subsequent to the termination, the Company has undergone a name change. As a result effective February 12, 2019, the Company’s name changed to Azure Health Technology Ltd.

BNYM has closed its books for issuance and cancellation.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbnymellon.com.

Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf.

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.